Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways
Publication date: Available online 19 March 2020Source: Saudi Pharmaceutical JournalAuthor(s): Abdullah F. AlAsmari, Nemat Ali, Fawaz AlAsmari, Wael A. AlAnazi, Musaad A. AlShammari, Naif O. Al-Harbi, Ali Alhoshani, Homood M. As Sobeai, Mohammed AlSwayyed, Mohammed M. AlAnazi, Nader S. AlGhamdi
Source: Saudi Pharmaceutical Journal - Category: Drugs & Pharmacology Source Type: research
More News: Cardiology | Drugs & Pharmacology | Heart | Middle East Health | Saudi Arabia Health | Victoza